Late Gastrointestinal Toxicity After Dose-Escalated Conformal Radiotherapy for Early Prostate Cancer: Results From the UK Medical Research Council RT01 Trial (ISRCTN47772397)

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 3, 2010, Pages 773-783

  Syndikus, Isabel ^a   Morgan, Rachel C ^b   Sydes, Matthew R ^b   Graham, John D ^c   Dearnaley, David P ^d  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c MUSGROVE PARK HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Conformal radiotherapy; Dose escalation; Late gastrointestinal toxicity; Phase III trial; Prostate cancer

Indexed keywords

CANCER THERAPY; CONFORMAL RADIOTHERAPY; CUMULATIVE INCIDENCE; DOSE ESCALATION; GASTROINTESTINAL TOXICITIES; HAZARD RATIO; LATE EFFECTS; LOCALIZED PROSTATE CANCER; LONG-TERM FOLLOW-UP; MEDICAL RESEARCH COUNCILS; NEOADJUVANT RADIOTHERAPY; NORMAL TISSUE; PROSTATE CANCERS; RADIATION THERAPY ONCOLOGY GROUPS; SIDE EFFECT; UNIVERSITY OF CALIFORNIA , LOS ANGELES;

ONCOLOGY; RADIATION EFFECTS; TOXICITY;

RADIOTHERAPY;

ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT;

ARTICLE; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; EARLY CANCER; FECES INCONTINENCE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; INTESTINE OBSTRUCTION; INTESTINE STENOSIS; INTESTINE ULCER; MAJOR CLINICAL STUDY; MALE; PELVIS PAIN SYNDROME; PREVALENCE; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RADIATION DOSE; RADIATION HAZARD; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RECTUM INJURY; RECTUM SURGERY; TENESMUS; TOXICITY TESTING;

DIARRHEA; GASTROINTESTINAL HEMORRHAGE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; NEOPLASM STAGING; PROCTITIS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECTAL DISEASES; RECTUM;

EID: 77952590675     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.052     Document Type: Article

References (31)

1. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
2. Peeters S.T.H., Heemsbergen W.D., Koper P.C., et al. Dose response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter phase III randomized trial comparing 68 Gy with 78 Gy. J Clin Oncol 24 (2006) 1990-1906
3. Al-Mamgani A., Van Putten W.L.J., Heemsbergen W.D., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008) 980-988
4. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 294 (2005) 1233-1239
5. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92 (2005) 488-498
6. Dearnaley D.P., Sydes M.R., Langley R.E., et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localized prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol 83 (2007) 31-41
7. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
8. Sydes M.R., Stephens R., Moore A., et al. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): Methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol 72 (2004) 199-211
9. Brenner H., and Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: Population-based estimates for the year 2000 by period analysis. J Clin Oncol 23 (2005) 441-447
10. Pilepich M.V., Asbell S.O., Krall J.M., et al. Correlation of radiotherapeutic parameters and treatment related morbidity-analysis of RTOG Study 77-06. Int J Radiat Oncol Biol Phys 13 (1987) 1007-1012
11. LENT SOMA tables. Radiother Oncol 35 (1995) 17-60
12. Litwin M.S., Hays R.D., Fink A., et al. The UCLA prostate cancer index: Development, reliability, and validity of a health-related quality of life measure. Med Care 36 (1998) 1002-1012
13. Esper P., Mo F., Chodak G., et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50 (1997) 920-928
14. Koper P.C., Heemsbergen W.D., Hoogeman M.S., et al. Impact of volume and location of the irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1072-1082
15. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
16. Geinitz H., Zimmerman F.B., Thamm R., et al. Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer. Radiother Oncol 79 (2006) 341-347
17. Chan L.W., Ping X., Gottschalk A.R., et al. Proposed rectal dose constraints for patients undergoing definite whole pelvic radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008) 69-77
18. Heemsbergen W.D., Hoogeman M.S., Hart G.A., et al. Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1011-1018
19. DeCrevoisieur R., Tucker S., Dong L., et al. Increased risk of biochemical and local failure in patients with distended rectum on the CT planning for prostate radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 965-973
20. Heemsbergen W.D., Hoogeman M.S., Witte M.G., et al. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: Results from the Dutch trial of 68 Gy versus 78 Gy. Int J Radiat Oncol Biol Phys 67 (2007) 1418-1423
21. Skala M., Rosewall T., Dawson L., et al. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 690-698
22. Van Der Laan H.P., Van Den Bergh A., Schilstra C., et al. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1138-1145
23. Andreyev H.J., Vlavianos P., Blake P., and Dearnaley D. Gastrointestinal symptoms after pelvic radiotherapy: Role for the gastroenterologist. Int J Radiat Oncol Biol Phys 62 (2005) 1464-1471
24. Henderson A., Andreyev H.J.N., Stephens R., and Dearnaley D. Patient and physician reporting of symptoms and health-related quality of life in trials of treatment for early prostate cancer: Consideration for future studies. Clin Oncol 18 (2006) 735-743
25. Hanlon A., Schultheiss T.E., Hunt M.A., et al. Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys 38 (1997) 59-63
26. Livsey J.E., Routledge J., Burns M., et al. Scoring of treatment-related late effects in prostate cancer. Radiother Oncol 65 (2002) 109-121
27. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
28. Tol-Geerdink J.J., Leer J.W., van Lin E.N., et al. Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being. Int J Radiat Oncol Biol Phys 70 (2008) 42-48
29. McNair H.A., Hansen V.N., Parker C.C., et al. A comparison of the use of bony anatomy and internal markers for offline verification and an evaluation of the potential benefit of online and offline verification protocols for prostate radiotherapy. Int J Radiat Oncol Biol Phys 71 (2008) 41-50
30. Gulliford S.L., Foo K., Morgan R.C., et al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: Evidence from the MRC RT01 trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys (2009) In press
31. Fonteyne V., Villeirs G., Speleers B., et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 72 (2008) 799-807